Oncolytic viruses are under intense development and have earned their place among the
novel class of cancer immunotherapeutics that are changing the face of cancer therapy …

Relatively little attention has been paid to the role of virotherapy in promoting antitumor
immune responses. Here, we show that CD8+ T cells are critical for the efficacy of …

Adenovirus is one of the most commonly used vectors for gene therapy and two products
have already been approved for treatment of cancer in China (Gendicine R and Oncorine …

Releasing the patient's immune system against their own malignancy by the use of
checkpoint inhibitors is delivering promising results. However, only a subset of patients …

Purpose: Reovirus is a naturally occurring oncolytic virus in clinical trials. Although tumor
infection by reovirus can generate adaptive antitumor immunity, its therapeutic importance …

Antigen-specific T cells circulate freely and accumulate specifically at sites of antigen
expression. To enhance the survival and targeting of systemically delivered viral vectors, we …

Purpose: The purpose of the present study was to investigate whether it is possible to
achieve truly systemic delivery of oncolytic reovirus, in immunocompetent hosts, using …

In many common cancers, dissemination of secondary tumors via the lymph nodes poses
the most significant threat to the affected individual. Metastatic cells often reach the lymph …

Innate immune effector mechanisms triggered by oncolytic viruses may contribute to the
clearance of both infected and uninfected tumor cells in immunocompetent murine hosts …

Our preclinical and clinical trials using a replication-defective adenoviral vector expressing
IFN-β have shown promising results for the treatment of malignant mesothelioma. Based on …